Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366647 | 1.00 | CES2 (0.40) | CES2CES1 | |
| SCHEMBL45430 | 0.79 | CES2 (0.53) | CES2CES1 | |
| SCHEMBL11355080 | 0.75 | CES2 (0.50) | CES2CES1 | |
| Ammonia Solution, Strong SCHEMBL3047305 | 0.75 | CES2 (0.50) | CES2CES1 | |
| SCHEMBL3975406 | 0.75 | CES2 (0.50) | CES2CES1 | |
| SCHEMBL942875 | 0.73 | — | — | |
| Hydrazine SCHEMBL3793747 | 0.72 | CES2 (0.48) | CES2CES1 | |
| Ethylene SCHEMBL28037152 | 0.72 | CES2 (0.48) | CES2CES1 | |
| SCHEMBL8726000 | 0.71 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL5716618 | 0.67 | CTSL (0.44) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | CES2 1256/4885CES1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.